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Summan- Analogues of the neurotransmitter substance P (SP) can interact with neuropeptide receptors. and
are reported to inhibit growth of small cell lung cancer cell lines (SCLC CLs). We found [D-Arg'. D-Phe'.
D-Trp 9. Leu"] substance P (D-Phe'SP) significantly inhibited DNA synthesis bv 10 10 human tumour CLs:
six SCLC. one N-SCLC (squamous). two ovarian and one squamous cervical carcinoma. with inhibition to
50'O control levels (ICi.) of 20-50p There was dose dependent inhibition of colony forming efficiency
(CFE) in 3 3 SCLC and 1 1 N-SCLC CL. ICio, of 0.5 -6.5 JAm in 50o serum. Exposure of SCLC CL HCI' to
100 jm D-Phe'SP for 1-4h caused a progressive fall in Viable cell number; surviving cells. grown in the
absence of peptide. showed a decreased growth rate. Dunng week's exposure of two SCLC CLs to 20 1wM
D-PhWSP. growth was slower than control cultures. while 50-100 ;m completely inhibited growth. These
inhibitorv effects were partially reversed by increasing serum concentration from 5 to 200o. but not bv SP.
vasopressin. bombesin or insulin-like growth factor 1. There was some inhibition of CFE by 3 3 normal
human bone marrows. ICos of 30-80 m. compared with 81A-Si for HC12 in 200o FCS. Therefore D-Phe'SP
appears to have more potent antiproliferative effects in tumour cells than normal cells. suggesting a role for
this analogue in tumour treatment.
Small cell lung cancer (SCLC) accounts for 250o of primary
lung cancers. While 70-800/o of patients respond to conven-
tional chemotherapy. fewer than 5% survive 5 vears. SCLC
synthesises a number of peptides. including bombesin (or its
mammalian homologue gastrin releasing peptide GRP) (Cut-
titta et al.. 1985) and insulin-like growth factor-I (IGF-1)
(Macaulay et al.. 1988). which appear to operate as autocrine
grow-th factors. Analogues which block the growth effects of
these factors may provide new approaches to therapy.
Substance P (SP) was first isolated in 1931 (Euler & Gad-
dum. 1931). It is a basic 11 amino acid sensory neurotrans-
mitter belonging to the Widely distributed tachykinin family.
Tachykinins possess a common C-terminal tripeptide Gly -
Leu-Met-NH.. The family includes substance K (neurokinin
A). neurokinin B. eledoisin. physalaemin, kassinin. uperlein
and phyllomedusin. Physalaemin-like peptides are produced
by SCLC cell lines (CLs) (Lazarus et al.. 1983). and have an
inhibitory effect on lung cancer cell growth in vitro (Bepler et
al.. 1987).
Tachykinins have a variety of physiological effects includ-
ing the contraction of smooth muscle, lowering blood pres-
sure and stimulatory effects on spinal or sensory neurons. SP
may also have a role in acute inflammation (Matsuda et al..
1989). SP analogues abolish the behavioural effects of SP
(Lembeck et al.. 1981). antagonise the effects of bombesin in
vivo (Yachnis et al.. 1984), and have potent local anaesthetic
actions (Piercey et al.. 1981; Post et al.. 1985).
Analogues of SP were found to block the release of amy-
lase from pancreatic acinar cells in vitro, by the competitive
inhibition of peptides which interact with the bombesin
receptor (Jensen et al., 1984). They also inhibited the mito-
genic stimulation of Swiss 3T3 cells by bombesin. vasopressin
and bradykinin (Corps et al., 1985; Woll & Rozengurt.
1988a). These peptides have no significant sequence homo-
logy with SP, and it has been suggested that SP analogues
recognise a common domain in the receptors for these neuro-
peptides, which is not the ligand binding site (Woll & Rozen-
gurt. 1988a).
Woll and Rozengurt (1988b) screened a panel of analogues
for antiproliferative effects in Swiss 3T3 cells. and [D-Arg'.
D-Phe'. D-Trp>9. Leu"] substance P (D-Phe'SP) was found
to be the most potent bombesin antagonist. The SP analo-
gues were shown to inhibit the growth of SCLC CLs (Woll &
Rozengurt. 1988b: Bepler et al.. 1989; Woll & Rozengurt.
1990). We have studied the effect of D-Phe'SP on grow-th on
ten human tumour cell lines and normal human cells.
Materials and methods
Cell lines
We are grateful to Dr G. Duchesne. Institute of Cancer
Research (ICR). Surrey. UK for SCLC CLs HX149 and
HC12. and to Dr A.F. Gazdar. National Cancer Institute.
Bethesda. USA for NCI-H226 (squamous lung carcinoma).
SCLC CLs lines ICR-SC112. ICR-SC132. ICR-SC65 and
ICR-SC17 were established in our laboratories (Everard et
al.. 1990). Fresh tumour cells (ICR-SC155) were obtained by
fine needle aspirate from a previously untreated SCLC
patient. The cells were incubated overnight in RPMI-1640
medium supplemented with 5% foetal calf serum (FCS) for
use in a 3H-thymidine incorporation assay. Excess cells were
later established as a cell line. All lung cultures were main-
tained at 37'C in RPMI-1640 supplemented with 5% FCS in
10% CO, in air. and were characterised biochemically and or
morphological as previously described (Carney et al.. 1985).
Dr L. Kelland. ICR. Surrey. UK kindly provided ovarian
carcinoma cell lines SKOV3 (originally from the American
Type Culture Collection) and CHI (Hills et al.. 1989).
HX155 (cervical squamous carcinoma cell line) (Kelland et
al.. 1987) and SF1 (normal human skin fibroblast cells).
These were grown in RPMI-1640 medium supplemented with
10% FCS. Normal human bone marrow samples were
obtained from bone marrow donors attending the Royal
Marsden Hospital. Belmont. Surrey.
Peptides
[D-Arg'. D-Phe'. D-Trp 9. Leu'1] substance P (D-Phe5SP.
substance P (SP) and bombesin were purchased from Penin-
sula Laboratonres Europe Ltd. St Helens. UK. [Arg8jvaso-
pressin was from Sigma Chemical Co Ltd. Dorset. UK.
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3H-thymidine was from Amersham International. UK.
Recombinant human Insulin-like growth factor 1 (rh-IGFI)
was kindly donated by Drs W. Marki and K. Scheibli.
Ciba-Geigy Ltd. Basel. Switzerland. Human glycosylated
recombinant granulocyte-macrophage colony stimulating fac-
tor (rh-GM-CSF) was kindly donated by Drs D. Gillespie
and M. Arden Jones of Sandoz. UK.
Gronsth assays
All assays were performed in RPMI-1640 medium supple-
mented with 5Oo FCS unless stated otherwise.
DNA synthesis
DNA synthesis was measured by 'H-thvimidine incorporation
(Rozengurt & Heppel. 1975). Cells were inoculated at 6.000
cells well in RPMI-1640 supplemented with 5%-20% FCS.
and D-Phe5SP 1-1OOJM alone or in combination with SP
1 lOO-AM, IGF-1 0.1-70nM. vasopressin 1-1.OO0nM or
bomesbin 1-1.000 nM. Control cells received an equivalent
volume of phosphate buffered saline (PBS). After 24 h incu-
bation (37°C. 10% CO, in air) cells were labelled with 0.4gsCi
3H-thymidine well (to give a final volume of 200 lI well) and
were harvested on an Inotech cell harvester following a fur-
ther 24 h incubation.
Cell growt th
Cultures of SCLC CLs HC12 and ICR-SC155 were grown at
2 x 1-; cells ml in the presence of 0. 20. 50 or 100 lm
D-Phe5SP. After 1 week cell number was determined bv
Coulter Counter, and viabilint assessed by trypan blue ex-
clusion on a haemocvtometer. Normal human skin fibro-
blasts (SF1) at 10' cells ml-l were grown in RPMI-1640
medium supplemented with 10% FCS. which was replaced
after 1 week with RPMI-1640 supplemented with 5%0 FCS
and 0. 50 or 100pJ, D-Phe'SP. After 3 davs the monolayer
was trvpsinised and viable cells were counted as above.
To assess the effect of short term exposure to the analogue
aliquots of 106 HC12 cells were treated with PBS (control) or
100 pm D-Phe'SP. At hourly intervals control and treated
cells were washed (centrifuged at 90 g for Smn in RPMI-
1640 medium with 5% FCS) and viable cells were counted on
a haemocytometer. The cells were then cultured in fresh
medium without the analogue, and viable cells were counted
after 1 week.
Clonogenic assaY
Lung tumour cells were seeded at 5 x I0' 2 x I0 plate in
0.5 ml 0.3% agar. and layered over an underlay of 1 ml 0.5%
agar containing D-Phe5SP 0-100 JAM or SP 0-100 JM. After
2-4 weeks incubation colonies of ) 50 cells were counted.
Bone marrow samples for clonogenic assay were layered
onto Ficoll-Hypaque and centrifuged at 550 g for 20 mmn.
Nucleated cells were collected from the interface, washed and
counted on a Coulter Counter. Cells were plated at 1IW dish
in a double layer assay as above, with a final concentration
of 20% FCS and 100 ng ml-' GM-CSF. HC12 cells were set
up in clonogenic assay under identical conditions.
Statistics
Results represent mean ± s.e.m. of a minimum of three repli-
cates and are expressed as % control. Analysis of variance
and the 2-tailed Dunnetts test were used to determine the
significance of differences between control and treated
groups, and Tukeys test were used to test for significant
differences between treated groups.
Results
Inhibition of3H-thvmidine incorporation in human cancer cell
lines and normal tissue
The substance P analogue D-Phe5SP was tested against six
SCLC CLs. one fresh SCLC tumour sample, one squamous
lung carcinoma CL. two ovarian carcinoma CLs and one
squamous cervical carcinoma CL. The minimum concentra-
tion required to cause significant inhibition (P<0.01) of
DNA synthesis varied with the cell line. Five of ten CLs were
inhibited by 10JAm D-Phe5SP (80-90% control). 4 10 by
20 JAm (70-83o% control), and 1 10 by 50 JAM (58 ± 20% con-
trol). Two of ten CLs (CHI and HX155) showed significant
stimulation (P<0.01) at 1 JM (115-116% control). Fresh
SCLC tumour cells (ICR-SC155) were inhibited by 10 JM
D-Phe5SP (87 ± 3% control). D-Phe5SP concentrations above
these minimum inhibitorv levels led to increased inhibition
and 3H-thymidine incorporation was negligible at 100 JAm
D-Phe5SP in all cell lines. Figure 1 shows representative
results in SCLC CL ICR-SC 1 12.
Inhibition to 50% of control (ICo) in 5% FCS was also
variable: 20-30 JM in six SCLC cell lines. 20 pm in fresh
SCLC tumour cells. 40 JAm in a squamous lung carcinoma
cell lines, 20-50 JAm in two ovarian carcinoma cell lines and
30 JM in a cervical carcinoma cell line (Table I). In HC'2
(SCLC CL). increasing the serum concentration from 5Oo to
10% to 20% FCS resulted in IC*s of approxmatelv 20. 40
.5
c
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Figre 1 ICR-SC112 (SCLC CL) dose response to 1-1001im
D-Phe'SP (U) and 1 -100 tiM substance P (*). 3H-thvmidine
incorporation expressed as 0O control incorporation (mean±
s.e.m.). *Significant inhibition P<0.01.
Table I The concentration of D-PheSP (puM) required to inhibit
'H-thvmidine incorporation into DNA to approximatelv 50°00 of
control (ICO)
Cell line D-PheSP IC.e, (JL.u SP
HC12 (SCLC) 20 NS
HX149 (SCLC) 25 100 (86± 500O)
ICR-SC1 12 (SCLC) 20 NS
ICR-SC132 (SCLC) 30 100 (80 ± 20o)
ICR-SC65 (SCLC) 30 ND
ICR-SC17 (SCLC) 30 ND
ICR-SC155 (SCLC) 20 ND
NCI-H26 (NSCLC) 40 NS
SKOV 3 (Ovanran) 50 NS
CHI (Ovarian) 20 100 (72±20O)
HX155 (Cervix) 30 NS
SFI (Fibroblasts) 50 NS
The lowest concentration of substance P (SP 1-100 JAM) which
causedsignificant inhibtion (P<0.01) of3H-thymidine incorporation is
also shown (mean±s.e.m. of control). All assays performed in the
presence of 5% FCS. NS = not significant. ND = not done.
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and 60gM respectively (Figure 2). Normal human skin fibro-
blasts (SF1) showed stimulation (132-155% control P<0.01)
of DNA synthesis at 1-20gM D-Phe5SP, however >,40;LM
caused inhibition (65 ± 4% control P<0.01). The IC50 was
50JM (Table I).
Substance P (SP) itself had no significant growth inhibitory
effect in 5/8 cell lines, while 3/8 showed inhibition (70-90%
control P<0.01) at 100gM. SP 1-1I00LM had no significant
effect on DNA synthesis in normal human skin fibroblasts
(SF1) (Table I).
SP (100IM), bombesin (1 PuM), vasopressin (1 gM) and
IGF-1 (70nM) were tested in combination with D-Phe5SP
(1-100tiM), to see if they were able to reverse the inhibitory
effect of the analogue. No reversal was seen in 3,3 SCLC
CLs or 1 1 squamous lung carcinoma CL. This was further
investigated in SCLC CL HX149 where inhibition (P<0.01)
at 20gtM D-Phe5SP in RPMI-1640 supplemented with 5%
FCS (56 ± 5% control) and 5tiM in unsupplemented RPMI-
1640 (68 ± 2% control) was not reversed by bombesin
(I -1,000 nM), vasopressin (I-1,000 nM) or SP (I -100pM)
(data not shown).
Inhibition ofgrowth as assessed by cell number
One week's exposure to 20, 50 or 100ALM D-Phe5SP resulted
in the growth inhibition of SCLC CLs HC12 and ICR-
SCI55. Increase in cell number was significantly inhibited
(P<0.01) by 20 tM (78 ±1% and 32 ± 0.4% control respec-
tively), while 50 and 100 gm caused cell number to fall below
the initial cell inoculum (Figure 3). In contrast 50 gM D-
Phe5SP had no effect on the cell number of confluent cultures
of normal human skin fibroblasts, however 100gm caused
inhibition to 83 ± 2% control (P<0.01) (Figure 3).
Effect ofshort term exposure to 100 gM.W analogue
HC12 viable cell number dropped on exposure to 1001M
D-Phe5SP for 1-4 h. After I h the treated cell number fell to
55 ± 4% of the initial inoculum, and by 4 h it was I ± 0.lI%
(Figure 4a). The control cell number recoverable over 4 h
was 78 ± 4-90 ± 9% of the initial inoculum.
Surviving treated and control cells were washed and cul-
tured in fresh medium without D-Phe5SP. After I week the
control cells had grown to 1706 ± 51-2530 ± 59% of the
initial cell number. Cells pre-exposed to D-Phe5SP for I h
showed similar growth to controls. However, cells which had
survived 2. 3 and 4 h exposure had a significantly (P<0.01)
reduced ability to grow. with cell number increases of
647 ± 20%, 224 ± 4% and 335 ± 7% respectively (Figure
4b). The same effects were found in two separate experi-
ments, both carried out on the HC12 cell line.
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Figure 3 Inhibition of growth of SCLC CLs HC12 and ICR-
SC155 after I week in the presence of 20. 50 or 100FM D-
Phe5SP. Effect of 3 days exposure to 50 and 100FAM D-Phe5SP on
cell number of confluent cultures of normal human skin fibro-
blasts (SF1). Results expressed a % control cell number (mean+
s.e.m.). *Sigm'ficant inhibition P<0.01.
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Figre 2 D-PheiSP (1- 100 M) effect on DNA synthesis of
HC12 (SCLC CL) in the presence of 5% FCS (U), 10% FCS
(A). and 20% FCS (V). Results expressed as % control incor-
poration (mean ±s.e.m.).
Fgure 4 a. HC12 viable cell number recovered after 1-4 h
exposure to PBS (A) or 100;iM D-Phe5SP (-). expressed as %
of initial inoculum of 106 cells (mean±s.e.m. oftriplicate counts).
Surviving cells from each time point were seeded at 8.5 x I03
ml-' and grown for 1 week in the absence of analogue. b.
Histogram showing growth of control (C) and treated (T) cells
after 1, 2, 3 or 4 h pre-exposure to 100FLM D-PheSP. Cell counts
expressed as % growth increase from original cell number (mean+
s.e.m. oftrplicate counts). *Significant inhibition (P<0.01) com-
pared to control.
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D-PhefSP effect on colony forming efficiency (CFE) ofcell
lines and normal human bone marrow
D-Phe5SP caused dose dependent inhibition of colony forma-
tion (P<0.01) in 3 3 SCLC CLs and 11 squamous lung
carcinoma CL. while substance P had no effect (Table II).
Significant inhibition was seen at D-Phe5SP concentration as
low as 1 gM.
Three normal human bone marrow samples showed vanr-
able inhibition (P<0.01) of colony formation in response to
D-Phe5SP. Two of three had an IC^O of 30JiM. while the third
had an IC;, of 80gM. However the degree of inhibition was
less than that seen in HC12 under the same growth condi-
tions (Table II). In 20%o FCS with GMCSF. 1 JiM D-Phe'SP
had no effect on the CFE of HC12. whereas this concentra-
tion had caused inhibition (31 ± 20%. P<0.01) in medium
with 5% FCS.
Discxs
This study confirms previous reports of the potent antipro-
liferative effects of [D-Arg1. D-Phe'. D-Trp 9. Leu11]substance
P (D-Phe5SP) on small cell lung cancer (SCLC) cell lines
(Woll & Rozengurt. 1988b; Woll & Rozengurt. 1990) (Figure
1). In addition. we have demonstrated equivalent inhibition
of DNA synthesis in fresh SCLC tumour cells from a pre-
viously untreated patient. a squamous lung carcinoma cell
line. a squamous cervical carcinoma cell line. and two
ovarian carcinoma cell lines (Table I).
Previous studies have focused on the ability of the SP
analogues to antagonise interaction of neuropeptide growth
factors. particularly bombesin. with cell surface receptors
(Woll & Rozengurt. 1988a: Woll & Rozengurt. 1988b: Taku-
wa et al.. 1990). Squamous lung carcinoma cell line NCI-
H226 lacks detectable bombesin receptors (Moody et al..
1983) and appears to be slightly less sensitive to the analogue
than the SCLC cell lines. However growth was undoubtedly
inhibited (Table II). Exogenous bombesin was not able to
reverse D-Phe5SP inhibition of DNA synthesis in the three
SCLC cell lines examined. which confirms previous sugges-
tions that the analogue is not working solely by competition
for binding to the bombesin receptor (Takuwa et al.. 1990).
This is in contrast with results in Swiss 3T3 cells. where the
inhibitory effects of SP analogues can be reversed by excess
gastrin releasing peptide (GRP) (Woll & Rozengurt. 1988b).
and suggests that the mechanism of inhibition is different in
the SCLC cells. Similarly. we saw no reversal of inhibition in
the presence of vasopressin or IGF1. Increasing serum con-
centration does partially reverse the inhibitory effect of the
analogue. however even in the presence of 20% FCS DNA
synthesis and cell growth are almost completely blocked
(Figure 2 and Table II).
Table II °o colony formation (mean± s.e.m. ofcontrol) inthepresence
of 0-100 tLM D-PheiSP and 0-100 jIM substance P (SP)
D-Phe-5SP pL- SP 1U
Cell line 0 1 10 50 1(X 0-100
HC12 100± 14 31 ±2a 5±2a 1+ la a NS
ICR-SCl'2 100± 11 8±2 0' oa oa NS
HX149 100±8 93± 14 oa 0a 0' NS
NCI-H226 100± 13 102± 16 16±2a 20±4' 7±2' NS
BM 1 100±5 120±12b 88±5 83±2 30±1' ND
BM 2E 100±5 98±9 70±8' 31±3' 20±3a ND
BM 3 * 100±5 96±5 87±4 11±3a 7±2a ND
HC12 * 100±8 123±6 19±1' 2±0.6' 0.6±0.6a ND
Assays performed in RPMI 1640 medium wlith 50O FCS except bone
marrow (BM) and HC12 assays (-) which were in RPMI 1640
supplemented with 200o FCS and 100 ng GM-CSF ml-'. 'Significant
inhibition P<0.01: bSignificant stimulation P<0.05; NS = not
significant; ND = not done.
SP analogue [D-Arg'. D-Pro. D-Trp 9. Leu"]substance P
(DAPTL-SP) is reported to have a cytostatic effect in SCLC
CLs. with reversal of growth inhibition after washing and
recultunrng in medium without the analogue (Woll & Rozen-
gurt. 1988b). We observed a significant reduction in viable
cell number following brief exposure to D-Phe5SP 100gM.
and the growth potential of the surviving cells was not
completely restored on removal of the analogue (Figure 4b).
This difference in reversibility may simply reflect the reported
increased potency of D-Phe5SP over DAPTL-SP (Woll &
Rozengurt. 1988b). or they may be inhibiting growth through
different mechanisms.
In general D-Phe'SP was less potent when tested against
normal human skin fibroblasts (Figure 3) and human bone
marrow cells (Table II) than tumour cells. Comparing the
growth inhibitorv effects of D-Phe5SP against HC12 and
human bone marrow samples which were grown under iden-
tical assay conditions, colony formation was consistently
higher by the bone marrows than the tumour cells. even at
1001 M. This differential effect between normal and tumour
cells could be due to the number or type of receptors ex-
pressed on the cell membrane.
In summary D-Phe5SP shows antitumour effects against
several different tumour cell types. including SCLC. squa-
mous lung carcinoma, ovarian and squamous cervical carcin-
oma. with less growth inhibition seen against normal human
skin fibroblasts and bone marrow. There is substantial cell
death after 2-4 h exposure to 100 jim D-Phe5SP. and surviv-
ing cells exhibit growth inhibition. These results suggest that
D-Phe5SP merits further study as a potential novel anti-
tumour agent. We are currently investigating the mechanism
of action and in vivo activity.
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